UroLift is marketed as a treatment for an enlarged prostate which is called BPH, Benign Prostatic Hyperplasia.
BPH is common and affects 40 million American men. Approximately 40% of men in their fifties and 70% of men in their sixties have BPH. BPH greatly affects men’s quality of life.
According to the manufacturers, the UroLift System breaks the cycle of medications and relieves the symptoms of an enlarged prostate.
It has been suggested that BPH medication causes sexual dysfunction, dizziness, and fatigue. Therefore, with UroLift you can enjoy a normal life.
How Does It Work – The Science Behind Urolift
The UroLift System treatment is accomplished at a doctor’s office using implants to open the obstruction and create a normal urine flow.
The UroLift Device is placed in the urethra to access the enlarged prostate. UroLift Implants lift and hold the enlarged prostate tissue and increase the opening of the urethra.
What are the Components of the UroLift Device?
According to a study in Medical Devices: Evidence and Research, it is a permanent implant of a nitinol capsular tab, stainless steel urethral end piece and a polyethylene teraphthatlate monofilament.
UroLift Pros & Cons
- Fast and effective
- One time, in office solution
- None of the risks of traditional surgery
- Breaks the cycle of medication
- Speedy recovery
- US Food and Drug Administration approval
- Safe and Sustained symptom relief
- Not appropriate for men with very large prostates
- Cannot be used for men with a large “middle lobe”
- pain or burning with urination
- blood in the urine
- pelvic pain
- urgent need to urinate
- inability to control the urge to urinate
Customer Questions and Answers
A: According to Urology Case Reports, the failure rate of the UroLift is 7% at 2 years and 14% at 4 years.
A: According to Texas Urology Specialists, studies show UroLift lasts approximately 3 years but may last longer.
A: According to Advanced Urology, pain and sensitivity while urinating during recovery is common.
A: The UroLift procedure can be repeated, or men can undergo a traditional laser procedure. It's also important to note that the UroLift procedure doesn't interfere with prostate cancer treatment.
A: Yes! The UroLift System treatment is covered by Medicare and many private insurers. Contact your insurance provider for your specific coverage information.
A: The device compresses the tissue and delivers tiny implants to lift and hold prostate tissue out of the way, thus opening the urethra.
A: You may be a good candidate if you are a male, 45 years of age or older, and have symptoms relating to BPH. Speak with your urologist to see if the UroLift System treatment is right for you.
UroLift Patient Reviews & Results
A review of 7 studies of 440 patients who had the UroLift procedure resulted in these findings:
All patients were over 50 with moderate symptoms. The procedure takes 50 minutes and half of patients used local anesthesia.
Patients experienced a modest improvement in symptoms over 12 months of follow-up. The sexual function did not change. The results indicate the procedure is safe.
However, it was noted that those with very large glands and severe symptoms should consider using alternative therapies.
Where can you have this procedure performed and how much does it cost?
According to ClinicoEconomics and Outcomes Research it costs approximately 6,000 dollars. The System is covered 100% by Medicare and most major private payors. The procedure can be performed by a urologist who has comprehensive training in the UroLift System.
The Bottom Line
The UroLift System is designed to treat an enlarged prostate called BPH, Benign Prostatic Hyperplasia, by placing implants to open the obstruction and increase urine flow. It is an alternative treatment to the medications that may cause dizziness, sexual dysfunction and fatigue.
Traditional surgery is therefore avoided, and it can be done in the doctor’s office with a fast recovery. It has been approved by the FDA and is considered safe and effective.
The procedure is usually covered 100% by Medicare and most major private payors.